veltuzumab
mAbexperimental
Veltuzumab is a monoclonal antibody which is being investigated for the treatment of non-Hodgkin's lymphoma. As of December 2011, it is undergoing Phase I/II clinical trials. When used with milatuzumab it showed activity. — Wikipedia
Clinical trial activity
9 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
9
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2004 (NCT00596804)
Timeline
Indications
Studied for
- Arthritis, Rheumatoid · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Leukemia, Prolymphocytic · Phase 1/Phase 2
- Lymphoma · Phase 1/Phase 2
- Lymphoma, B-Cell · Phase 1/Phase 2
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 1/Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Purpura, Thrombocytopenic, Idiopathic · Phase 1/Phase 2
- Squamous Intraepithelial Lesions · Phase 1/Phase 2
Mechanism of action
- B-lymphocyte antigen CD20BINDING AGENT
B-lymphocyte antigen CD20 binding agent
Induces apoptosis, Antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
Induces apoptosis, Antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVeltuzumab ↗
- ChEMBLCHEMBL1743088 ↗
Also known as
- ha20
- ha20
- immu-106
- immu-106
- monoclonal antibody immu-106
- veltuzumab
- veltuzumab
- veltuzumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01390545 | Phase 2 | Aug 1, 2011 | Takeda |
| NCT01147393 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2010 | Cornell University, Immunomedics |
| NCT01101581 | Phase 1/Phase 2 (Phase 2) | May 1, 2010 | Immunomedics |
| NCT01279707 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2010 | Immunomedics, University of London |
| NCT00989586 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2009 | Immunomedics, Ohio State University |
| NCT00546793 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2008 | Immunomedics |
| NCT00547066 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2007 | Immunomedics |
| NCT00285428 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2004 | Immunomedics |
| NCT00596804 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2004 | Immunomedics |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immunomedics | For profit | 8 | 5 | 1 | 2004 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Takeda | For profit | 1 | 1 | 1 | 2011 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2010 |
5 organizations
Page 1 / 1